Mauricio Burotto

机构：Universidad de Los Andes, Chile, Clínica Alemana, Finis Terrae University · ORCID：0000-0002-7150-4033

发表论文 171 篇 · 总被引 9108 次 · h-index 36

代表论文

• Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial (2025 · Annals of Oncology · 被引 20)
• Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial. (2025 · Journal of Clinical Oncology · 被引 20)
• Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee (2025 · Journal for ImmunoTherapy of Cancer · 被引 14)
• Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma (2025 · Annals of Oncology · 被引 7)
• Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study. (2026 · Journal of Clinical Oncology · 被引 4)
• Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial (2026 · The Lancet · 被引 1)